In 2019, Victoria became the first person in the world with sickle cell disease to receive CRISPR gene-editing therapy as part of a clinical trial. At the time, no one knew whether the treatment would work, how long the results would last, or what the future might hold. She wasn't simply receiving a new treatment—she was helping scientists answer one of the biggest questions in modern medicine.

"I don't tell patients they should join a clinical trial. I tell them they deserve to know whether a clinical trial is an option. My role is to help patients understand their choices so they can make the decision that's right for them."

Over the last few years, I've had the privilege of working directly with patients and caregivers across the country through Karen's Club, helping individuals navigate difficult cancer diagnoses, understand biomarker testing, explore clinical trial options, and make informed decisions about their care.

A recent visit to New Orleans became a unique opportunity to have conversations about health, access to care and the importance of taking action early and getting those wellness screenings.

Check out our highlights from ASCO 2022 that may have a real impact on patients of color like us!